Morfina Isab Laboratórios Basi (Morphine Hydrochloride Trihydrate)

Morphine Hydrochloride Trihydrate, the active ingredient in Morfina Isab Laboratórios Basi, is an opioid analgesic presented as an injectable solution for epidural, intramuscular and intrathecal use. It provides analgesia for severe acute, postoperative and cancer‑related pain in adult patients.

GNH USA supplies Morfina Isab Laboratórios Basi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Morphine acts on the mu‑opioid receptor pathway to relieve severe pain. It is indicated for: - Severe acute pain: delivers rapid, potent analgesia for intense short‑term pain episodes. - Post‑operative pain: manages pain following surgical procedures to improve recovery. - Cancer‑related pain: controls persistent malignant pain when other analgesics are insufficient.

Morphine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: feeling of sickness often accompanied by an urge to vomit. - Constipation: reduced bowel movements and hard stools. - Drowsiness: increased sleepiness or fatigue. - Dizziness: sensation of light‑headedness or unsteadiness. - Sweating: excessive perspiration unrelated to temperature. - Dry mouth: reduced salivation leading to a parched feeling.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing that can be life‑threatening. - Severe hypotension: marked drop in blood pressure causing faintness. - Bradycardia: abnormally slow heart rate. - Dependence or addiction: development of physical or psychological reliance. - Adrenal insufficiency: impaired adrenal gland function. - Anaphylaxis: rare severe allergic reaction with rash, swelling, and airway compromise.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for safety concerns. - Assess pain level: determine severity and appropriate opioid requirement. - Monitor respiratory function: observe breathing rate and oxygen saturation, especially after dose changes. - Adjust for organ impairment: reduce dose in renal or hepatic dysfunction. - Avoid concurrent CNS depressants: limit use with benzodiazepines, barbiturates, or alcohol. - Use caution in the elderly: start with lower doses and titrate slowly. - Store at ambient temperature: keep in original container, protect from moisture and light.

Morphine can interact with other medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension or serotonin syndrome. - Other opioids: additive respiratory depression and sedation.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines, antihistamines): may enhance sedation. - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): increase morphine plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): decrease morphine effectiveness.